Diabetes Industry 2026

View Trends, Analysis and Statistics.

1 000+ Diabetes Industry reports covering 200 countries — revenue data, market shares and forecast 2026-2030.

North American Diabetes Industry 2026‑2030

North America: 51M adults with diabetes; ~14% regional prevalence. Eli Lilly, Novo Nordisk, Dexcom and Insulet dominate drugs and devices. Incidence, prevalence & mortality forecasts by market, 2026-2030.

View this report >

European Diabetes Industry 2026‑2030

Europe: 61M adults with diabetes; 1 in 11 adults affected regionally. Novo Nordisk, Sanofi, Roche and Ypsomed lead the European landscape. Country-level prevalence & mortality forecasts for 2026-2030.

View this report >

Global Diabetes Industry 2026‑2030

Global: 537M adults with diabetes, projected to reach 643M by 2030. Novo Nordisk, Eli Lilly, Sanofi, Abbott and Dexcom lead worldwide. Regional forecasts, prevalence & mortality data, 2026-2030 horizon.

View this report >

US Diabetes Industry 2026‑2030

US: 38.4M people with diabetes (11.6% of population); care market growing ~7% CAGR. Eli Lilly, Novo Nordisk, Dexcom and Abbott dominate drugs and CGM devices. Segment forecasts, prevalence & mortality trends, 2026-2030 horizon.

View this report >

Asian Diabetes Industry 2026‑2030

Asia accounts for over 300M adults with diabetes, roughly 60% of global cases. Novo Nordisk, Eli Lilly and regional generics makers shape the competitive field. Includes incidence, prevalence & mortality trends with 2026-2030 forecasts.

View this report >

Any questions? Get in touch with Emilie

+33 4 37 65 17 06

+61 280 114 871

+1 718 303 2384

+852 8199 0067

+44 207 193 2091

+44 207 193 2091

ReportLinker Rating

96%

of our customers give us a high rating on Trustpilot and G2 platforms

More countries